Association of Gut Microbiota With Intestinal Ischemia/Reperfusion Injury
Jingyi Chen
Yu Wang1† - 1Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan, China
- 2Department of Surgical Nursing, Taihe Hospital, Hubei University of Medicine, Shiyan, China
- 3Physical Examination Center, Shiyan Hospital of Integrated Traditional and Western Medicine, Shiyan, China
Intestinal ischemia/reperfusion (II/R) is a common acute and critical condition in clinical practice with a high mortality rate. However, there is still a lack of effective prevention and treatment measures for II/R injury. The role of the gut microbiota in II/R has attracted widespread attention. Recent evidence has demonstrated that the gut microbiota plays a pivotal role in the occurrence, development, and prognosis of II/R. Therefore, maintaining the homeostasis of gut microbiota and its metabolites may be a potential strategy for the treatment of II/R. This review focuses on the importance of crosstalk between the gastrointestinal ecosystem and II/R to highlight II/R-induced gut microbiota signatures and potential applications of microbial-based therapies in II/R. This will also provide potentially effective biomarkers for the prediction, diagnosis and treatment of II/R.
Introduction
Intestinal ischemia/reperfusion (II/R) injury is a clinical emergency with high morbidity and mortality due to a dramatic reduction in intestinal blood supply, which is associated with mesenteric artery thrombosis, strangulated ileus, trauma, abdominal aortic aneurysm surgery, intestinal transplantation and other clinical conditions (Ma et al., 2020, Wu et al., 2021a). Intestinal ischemia results in cellular damage and impaired intestinal mucosal barrier function during reperfusion, leading to systemic inflammatory response syndrome, multiple organ dysfunction syndrome, and even death (Gutiérrez-Sánchez G et al., 2021). II/R will not only cause damage to the intestinal tissue itself, but also damage to distant organs. Gut microbiota is a general term for a group of microbial communities living in the body’s gut (de Wouters d’Oplinter et al., 2021; Qi et al., 2021; Hosseinkhani et al., 2021). In recent years, more and more research evidence has shown that the gut microbiota is directly related to the occurrence of various human diseases (Bhattarai et al., 2021; Cao et al., 2021; Deng et al., 2021c; Li et al., 2021; Prochazkova P et al., 2021; Rao et al., 2021). The research on the changes and potential roles of gut microbiota in II/R has rapidly increased, which has attracted widespread attention. In this review, we aimed to summarize changes and potential diagnostic, therapeutic or exacerbating roles of gut microbiota in II/R, providing a solid theoretical basis and potentially effective biomarkers for the prevention and treatment of II/R injury.
II/R Overview and Current Dilemma
The intestinal tract plays an extremely important role in the normal life activities of the human body (Bruellman and Llorente, 2021). The gut is the core organ of human immunity, in which 60-70% of the immune cells of the human body are located in the gut to resist the invasion of foreign germs and toxins (Hou et al., 2020; Fan et al., 2021; Liu et al., 2021). In the daily diet and metabolism, the intestinal tract gathers the most important garbage and toxins in the human body, and will eventually be excreted through the feces, which is also an important channel for the excretion of more than 80% of the toxins in the human body (Zhao et al., 2021; Butt and Jenab, 2021; Chen et al., 2021). In addition, more than 97.5% of the nutrients necessary for the human body are obtained from the intestinal absorption (Tiffany et al., 2021); 95% of the core important hormones of the human body are produced by the intestinal tract, and it is currently known that the human gastrointestinal tract can secrete more than 35 kinds of hormones (Mayneris-Perxachs et al., 2020; Lin et al., 2021; Qi et al., 2021). The intestine is the second brain of the human body, with hundreds of millions of nerve cells and a complex neural network distributed. The neural network of the intestine is directly related to the brain, forming a brain-gut-bacteria axis, which affects the nervous system through the metabolism of intestinal flora (Rutsch et al., 2020; Aktar et al., 2020; Zhang et al., 2021). Furthermore, about 78% of the flora of the human body lives in the intestinal tract. The bacteria combine, restrict and depend on each other to form a micro-ecological balance, which maintains the absorption of nutrients, the discharge of toxins, the secretion of neurotransmitters and hormones, the stability of the neural network, and ensures the immunity of the human body. Therefore, health comes from the micro-ecological balance of the flora.
II/R is a common pathophysiological process of a variety of critical diseases and organ damage. It not only causes local inflammation and mucosal damage, but also systemic inflammatory response syndrome and multiple organ dysfunction syndrome. Therefore, it is of great clinical significance to protect the intestines in the perioperative period and to explore the intervention methods with clinical translation value by studying the mechanism of II/R hindgut injury and II/R extraintestinal organ (such as brain, lung) injury. The intestinal mucosal barrier is composed of mechanical barrier, chemical barrier, immune barrier and biological barrier. It is generally believed that the failure of the intestinal barrier function may lead to the longitudinal displacement of pathogenic bacteria and their metabolites from the intestinal lumen to the blood circulatory system, which in turn induces a chronic inflammatory response in the whole body, and even the failure of various organ functions. Diamine oxidase (DAO) is a highly active intracellular enzyme in the cytoplasm of human and all mammalian intestinal mucosal cells. When intestinal mucosal cells are damaged and necrotic, DAO is released into the blood, resulting in increased blood activity. Blood DAO level is a good indicator for monitoring intestinal mucosal damage (Bragg et al., 1991). D-lactic acid is a metabolite of intestinal bacteria. When the body is severely injured or infected, the intestinal mucosal ischemia and hypoxia cause the epithelial top of the intestinal mucosa to fall off, the permeability of the intestinal mucosa increases, and a large amount of D-lactic acid enters the bloodstream, while mammals do not has an enzyme system that breaks it down, so plasma D-lactic acid levels can be significantly increased (Günel et al., 1998). Therefore, the determination of D-lactic acid content in blood can reflect changes in the degree of intestinal mucosal ischemia and intestinal permeability. There are a large number of G-bacteria in the intestine, which can produce a large amount of endotoxin. When serious diseases such as severe trauma, burns and peritonitis occur, the permeability of the intestinal mucosa increases, the intestinal barrier function is destroyed, and endotoxin enters the blood, resulting in endotoxemia. Therefore, plasma endotoxin levels can also reflect the intestinal barrier function. At present, the detection of plasma DAO, D-lactic acid, and bacterial endotoxin levels is regarded as the main detection index of intestinal barrier function. However, there is still a lack of effective II/R diagnostic criteria and preventive measures in clinical practice.
Gut Microbiome
Gut microbiota is the microflora that lives in the human intestine. The number of bacteria in the human intestine is 40 trillion, and the total number of genes is about 150 times the number of human genes (Parker et al., 2020; Kazemian et al., 2020; Caparrós et al., 2021). It can be seen from the data that the gut microbiota is a very large group, so the intestinal flora is also called the “second genome”, “second brain” and “gut brain” of the human body (Liu et al., 2021, Tourlousse et al., 2021). The gut flora digests food components (Coker et al., 2021; Naimi et al., 2021), synthesizes essential vitamins (Li et al., 2020; Zafar and Saier, 2021), stimulates and modulates the immune system (Han et al., 2021a, Nogal et al., 2021), eliminates pathogens (Maslanka et al., 2020; Silwal et al., 2021), clears toxins and carcinogens (de Nies et al., 2021), supports gut function. Under normal circumstances, the gut microbiota can establish a dynamic ecological balance with the host and the external environment. Once the gut microbiota is disturbed and unbalanced, it will lead to the loss of various functions of the host, such as loss of barrier function, loss of inflammation and immune function, etc., thereby causing disease (Wang et al., 2020, Han et al., 2021b). It is reported that 95% of diseases are related to gut microbiota. In addition to gastrointestinal diseases, metabolic diseases, gut microbiota is also related to various system diseases, such as nervous system (Vicentini et al., 2021; Saldana-Morales et al., 2021), respiratory system (Zheng et al., 2020; Casaro et al., 2021), cardiovascular system (Khan et al., 2021; Deng et al., 2022), tumor (Yang et al., 2020; Chung et al., 2021; Murphy et al., 2021), etc. disease related. The gut microbiota mainly interacts closely with the host through small-molecule metabolites (such as short-chain fatty acids, bile acids, tryptophan, amino acids, etc.) (Dong et al., 2020; Kumari et al., 2020; Winston and Theriot, 2020; Guzior and Quinn, 2021; Sun et al., 2021; Wu et al., 2021b), affecting its occurrence, and therefore, there is a growing need to understand the importance of the microbiota in II/R development, diagnosis, and therapy.
II/R-Related Gut Microbial Signatures
Ischemia results in decreased blood flow and oxygen supply to the intestinal tissue, while reperfusion will promote the accumulation and burst of harmful factors such as reactive oxygen species and inflammatory factors. Changes in the gut microenvironment will inevitably lead to changes in the quantity or population of gut microbiota, and summarizing these changes will help us explore potential biomarkers for predicting and diagnosing II/R. As shown in Table 1, II/R leads to small intestinal bacterial overgrowth and the formation of ceramides in the jejunal vasculature, which may contribute to the intestinal permeability associated with this injury. The new discovery of ceramides in bacterial membranes represents a new opportunity to study the dynamic pathogenicity of the gut microbiome (Hoehn et al., 2016). II/R-induced changes in gut microbiota also differed in different intestinal segments. Denaturing gradient gel electrophoresis of the ileal microbiota revealed that the gut microbiota pattern changed early after II/R, with significant differences at 12 h of reperfusion, and then began to return to a normal pattern. Specific dysbiosis is characterized by proliferation of Escherichia coli and reduction of Lachnospiraceae and Lactobacilli (Wang et al., 2013b). Deng et al. found that the relative abundance of Firmicutes and Bacteroidetes in the ileum of mice in the II/R group was significantly increased, while the relative abundance of Verrucobacterium was significantly decreased (Deng et al., 2021). Colonic microbiota changed earlier, with significant differences 6 hours after reperfusion, and then began to recover. These changes were characterized by increases in Escherichia coli and Prevotella oralis, as well as proliferation of Lactobacilli and healing of epithelial cells (Wang et al., 2012).
Table 1 Intestinal ischemia/reperfusion-induced changes in gut microbiota.
The Effect of Gut Microbiota on II/R
Not only does II/R lead to changes in the gut microbiota, dysbiosis can also affect II/R. As shown in Table 2, depletion of gut commensals reduces B cell, Igs, and TLR expression in the gut, inhibits complement activation, and attenuates intestinal inflammation and injury after II/R (Yoshiya et al., 2011). The research has found that gut microbiota suppresses neutrophil hyperreactivity in II/R injury, while ensuring immunovigilance by enhancing neutrophil recruitment (Ascher et al., 2020). The use of antibiotics to clear the flora is an effective way to treat infections in clinical practice. Another method to correct intestinal flora disturbance is fecal microbiota transplantation. Fecal microbiota transplantation is to transplant the functional flora in the feces of healthy people into the patient’s gastrointestinal tract to rebuild new intestinal flora and achieve the treatment of intestinal and extra-intestinal diseases (Jing et al., 2021; Manrique et al., 2021; Trikha et al., 2021). Before II/R occurs, alterations in the gut microbiota may increase susceptibility to II/R through multiple mechanisms, including: (1) the expansion of pathogenic gut bacteria; (2) the activation of the immune system that produces strong pro-inflammatory response; (3) reducing the production of beneficial microbial products such as short-chain fatty acids. Hu et al. found that differences in the pre-II/R gut microbiota, especially in the abundance of Lactobacillus murinus, strongly influence II/R susceptibility and outcome. Moreover, the abundance of Lactobacillus murinus in preoperative feces of cardiopulmonary bypass patients was significantly negatively correlated with postoperative intestinal injury (Hu et al., 2022). Pretreatment of animals with Bifidobacteria prevented II/R-induced bacterial translocation, reduced proinflammatory cytokine release, endotoxin levels, intestinal epithelial apoptosis, disruption of tight junctions, and increased SCFA concentrations, leading to recovery microbiota and mucosal integrity (Wang et al., 2013b). Wang et al. revealed that pretreatment of animals with Lactobacillus plantarum completely prevented II/R-induced bacterial translocation, reduced proinflammatory cytokine release and intestinal epithelial apoptosis, thereby restoring microflora and mucosal integrity (Wang et al., 2011). Animals pretreated with Bifidobacterium bifidum PRL2010 showed lower neutrophil recruitment in the lungs, significantly reduced bacterial translocation, and reduced transcript levels of TNFα and IL-10 in liver and kidney, while suppressing pathogenic bacteria adhesion and enhancement of the host innate immune response are one of the possible protective mechanisms exerted by probiotics (Duranti et al., 2018). Hu et al. showed that Lactobacillus murinus attenuates II/R injury in mice via macrophages. In addition to intestinal bacterial strains, it has recently been found that intestinal flora metabolites are also non-negligible substances in II/R (Hu et al., 2022). Deng et al al. found that gut microbial metabolite pravastatin or capsiate attenuate II/R injury and improved the survival of mice, and pravastatin or capsiate levels in the preoperative stool of patients undergoing cardiopulmonary bypass were negatively correlated with the indices of postoperative intestinal I/R injury (Deng et al., 2021a, Deng et al., 2021b).
Table 2 The effect of gut microbiota on intestinal ischemia/reperfusion.
Once II/R occurs, disturbances in the gut microbiota are exacerbated and increase the likelihood of organ failure. Microbial treatments may be potentially effective approaches to reduce the risk of II/R and improve II/R outcomes in certain patient populations, but further studies are needed to demonstrate the safety of these treatments.
Conclusion
This review summarizes the characteristics of II/R-induced changes in gut microbiota, and also summarizes the application of gut microbiota and their metabolites in the prevention and treatment of II/R injury in recent years. Gut microbiota will also play an increasingly important role in the prediction, diagnosis and treatment of clinical II/R in the future. However, the current study of gut microbiota in II/R also has certain limitations. At present, most studies on gut microbiota focus on preclinical animal studies. How to make the results of basic research better applied to the clinic is the most pressing issue.
Author Contributions
YW and JC contributed equally to the writing of this manuscript; YS, YRL, CW, and YPL designed the illustrations. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by grants from Shiyan Taihe Hospital Scientific Research Supporting Fund (2019SCI013 to JC).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aktar, R., Parkar, N., Stentz, R., Baumard, L., Parker, A., Goldson, A., et al. (2020). "Human Resident Gut Microbe Bacteroides Thetaiotaomicron Regulates Colonic Neuronal Innervation and Neurogenic Function." Gut. Microbes 11 (6), 1745–1757. doi: 10.1080/19490976.2020.1766936
Ascher, S., Wilms, E., Pontarollo, G., Formes, H., Bayer, F., Müller, M., et al. (2020). "Gut Microbiota Restricts NETosis in Acute Mesenteric Ischemia-Reperfusion Injury." Arterioscler. Thromb. Vasc. Biol. 40 (9), 2279–2292. doi: 10.1161/atvbaha.120.314491
Bayer, F., Ascher, S., Kiouptsi, K., Kittner, J. M., Stauber, R. H., Reinhardt, C. (2021). "Colonization With Altered Schaedler Flora Impacts Leukocyte Adhesion in Mesenteric Ischemia-Reperfusion Injury." Microorganisms 9 (8). doi: 10.3390/microorganisms9081601
Bhattarai, Y., Si, J., Pu, M., Ross, O. A., McLean, P. J., Till, L., et al. (2021). "Role of Gut Microbiota in Regulating Gastrointestinal Dysfunction and Motor Symptoms in a Mouse Model of Parkinson's Disease." Gut Microbes 13 (1), 1866974. doi: 10.1080/19490976.2020.1866974
Bragg, L. E., Thompson, J. S., West, W. W. (1991). "Intestinal Diamine Oxidase Levels Reflect Ischemic Injury." J. Surg. Res. 50 (3), 228–233. doi: 10.1016/0022-4804(91)90183-m
Bruellman, R., Llorente, C. (2021). "A Perspective Of Intestinal Immune-Microbiome Interactions In Alcohol-Associated Liver Disease." Int. J. Biol. Sci. 17 (1), 307–327. doi: 10.7150/ijbs.53589
Butt, J., Jenab, M. (2021). "Association of Pre-Diagnostic Antibody Responses to Escherichia Coli and Bacteroides Fragilis Toxin Proteins With Colorectal Cancer in a European Cohort." Gut Microbes 13 (1), 1–14. doi: 10.1080/19490976.2021.1903825
Cao, J., Wang, C., Zhang, Y., Lei, G., Xu, K., Zhao, N., et al. (2021). "Integrated Gut Virome and Bacteriome Dynamics in COVID-19 Patients." Gut Microbes 13 (1), 1–21. doi: 10.1080/19490976.2021.1887722
Caparrós, E., Wiest, R., Scharl, M., Rogler, G., Gutiérrez Casbas, A., Yilmaz, B., et al. (2021). "Dysbiotic Microbiota Interactions in Crohn's Disease." Gut Microbes 13 (1), 1949096. doi: 10.1080/19490976.2021.1949096
Casaro, M. B., Thomas, A. M., Mendes, E., Fukumori, C., Ribeiro, W. R., Oliveira, F. A., et al. (2021). "A Probiotic has Differential Effects on Allergic Airway Inflammation in a/J and C57BL/6 Mice and is Correlated With the Gut Microbiome." Microbiome 9 (1), 134. doi: 10.1186/s40168-021-01081-2
Chen, L., Zhang, S., Wu, S., Ren, Z., Liu, G., Wu, J. (2021). "Synergistic Protective Effect of Konjac Mannan Oligosaccharides and Bacillus Subtilis on Intestinal Epithelial Barrier Dysfunction in Caco-2 Cell Model and Mice Model of Lipopolysaccharide Stimulation." Front. Immunol. 12. doi: 10.3389/fimmu.2021.696148
Chung, Y., Ryu, Y., An, B. C., Yoon, Y. S., Choi, O., Kim, T. Y., et al. (2021). "A Synthetic Probiotic Engineered for Colorectal Cancer Therapy Modulates Gut Microbiota." Microbiome 9 (1), 122. doi: 10.1186/s40168-021-01071-4
Coker, J. K., Moyne, O., Rodionov, D. A., Zengler, K. (2021). "Carbohydrates Great and Small, From Dietary Fiber to Sialic Acids: How Glycans Influence the Gut Microbiome and Affect Human Health." Gut Microbes 13 (1), 1–18. doi: 10.1080/19490976.2020.1869502
Deng, F., Hu, J. J., Yang, X., Sun, Q. S., Lin, Z. B., Zhao, B. C., et al. (2021a). "Gut Microbial Metabolite Pravastatin Attenuates Intestinal Ischemia/Reperfusion Injury Through Promoting IL-13 Release From Type II Innate Lymphoid Cells via IL-33/ST2 Signaling." Front. Immunol. 12. doi: 10.3389/fimmu.2021.704836
Deng, F., Zhao, B. C., Yang, X., Lin, Z. B., Sun, Q. S., Wang, Y. F., et al. (2021b). "The Gut Microbiota Metabolite Capsiate Promotes Gpx4 Expression by Activating TRPV1 to Inhibit Intestinal Ischemia Reperfusion-Induced Ferroptosis." Gut Microbes 13 (1), 1–21. doi: 10.1080/19490976.2021.1902719
Deng, Y., Zhou, M., Wang, J., Yao, J., Yu, J., Liu, W., et al. (2021c). "Involvement of the Microbiota-Gut-Brain Axis in Chronic Restraint Stress: Disturbances of the Kynurenine Metabolic Pathway in Both the Gut and Brain." Gut Microbes 13 (1), 1–16. doi: 10.1080/19490976.2020.1869501
Deng, F., Zhang, L. Q., Wu, H., Chen, Y., Yu, W. Q., Han, R. H., et al. (2022). "Propionate Alleviates Myocardial Ischemia-Reperfusion Injury Aggravated by Angiotensin II Dependent on Caveolin-1/ACE2 Axis Through GPR41." Int. J. Biol. Sci. 18 (2), 858–872. doi: 10.7150/ijbs.67724
de Nies, L., Lopes, S., Busi, S. B., Galata, V., Heintz-Buschart, A., Laczny, C. C., et al. (2021). "PathoFact: A Pipeline for the Prediction of Virulence Factors and Antimicrobial Resistance Genes in Metagenomic Data." Microbiome 9 (1), 49. doi: 10.1186/s40168-020-00993-9
de Wouters d'Oplinter, A., Rastelli, M., Van Hul, M. (2021). "Gut Microbes Participate in Food Preference Alterations During Obesity." Gut Microbes 13 (1), 1959242. doi: 10.1080/19490976.2021.1959242
Dong, F., Hao, F., Murray, I. A., Smith, P. B., Koo, I., Tindall, A. M., et al. (2020). "Intestinal Microbiota-Derived Tryptophan Metabolites are Predictive of Ah Receptor Activity." Gut Microbes 12 (1), 1–24. doi: 10.1080/19490976.2020.1788899
Duranti, S., Vivo, V., Zini, I., Milani, C., Mangifesta, M., Anzalone, R., et al. (2018). "Bifidobacterium Bifidum PRL2010 Alleviates Intestinal Ischemia/Reperfusion Injury." PLoS One 13 (8), e0202670. doi: 10.1371/journal.pone.0202670
Fan, L., Qi, Y., Qu, S., Chen, X., Li, A., Hendi, M., et al. (2021). "B. Adolescentis Ameliorates Chronic Colitis by Regulating Treg/Th2 Response and Gut Microbiota Remodeling." Gut Microbes 13 (1), 1–17. doi: 10.1080/19490976.2020.1826746
Günel, E., Cağlayan, O., Cağlayan, F. (1998). "Serum D-Lactate Levels as a Predictor of Intestinal Ischemia-Reperfusion Injury." Pediatr. Surg. Int. 14 (1-2), 59–61. doi: 10.1007/s003830050436
Gutiérrez-Sánchez, G., García-Alonso, I., Gutiérrez Sáenz de Santa María, J., Alonso-Varona, A., Herrero de la Parte, B. (2021). "Antioxidant-Based Therapy Reduces Early-Stage Intestinal Ischemia-Reperfusion Injury in Rats." Antioxidants (Basel) 10 (6). doi: 10.3390/antiox10060853
Guzior, D. V., Quinn, R. A. (2021). "Review: Microbial Transformations of Human Bile Acids." Microbiome 9 (1), 140. doi: 10.1186/s40168-021-01101-1
Han, H., Yi, B., Zhong, R., Wang, M., Zhang, S., Ma, J., et al. (2021a). "From Gut Microbiota to Host Appetite: Gut Microbiota-Derived Metabolites as Key Regulators." Microbiome 9 (1), 162. doi: 10.1186/s40168-021-01093-y
Han, Q., Wang, J., Li, W., Chen, Z. J., Du, Y. (2021b). "Androgen-Induced Gut Dysbiosis Disrupts Glucolipid Metabolism and Endocrinal Functions in Polycystic Ovary Syndrome." Microbiome 9 (1), 101. doi: 10.1186/s40168-021-01046-5
Hoehn, R. S., Seitz, A. P., Jernigan, P. L., Gulbins, E., Edwards, M. J. (2016). "Ischemia/Reperfusion Injury Alters Sphingolipid Metabolism in the Gut." Cell Physiol. Biochem. 39 (4), 1262–1270. doi: 10.1159/000447831
Hosseinkhani, F., Heinken, A., Thiele, I., Lindenburg, P. W., Harms, A. C., Hankemeier, T. (2021). "The Contribution of Gut Bacterial Metabolites in the Human Immune Signaling Pathway of Non-Communicable Diseases." Gut Microbes 13 (1), 1–22. doi: 10.1080/19490976.2021.1882927
Hou, Q., Huang, J., Ayansola, H., Masatoshi, H., Zhang, B. (2020). "Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases." Front. Immunol. 11. doi: 10.3389/fimmu.2020.623691
Hu, J., Deng, F., Zhao, B., Lin, Z., Sun, Q., Yang, X., et al. (2022). "Lactobacillus Murinus Alleviate Intestinal Ischemia/Reperfusion Injury Through Promoting the Release of Interleukin-10 From M2 Macrophages via Toll-Like Receptor 2 Signaling." Microbiome 10 (1), 38. doi: 10.1186/s40168-022-01227-w
Jing, Y., Yu, Y., Bai, F., Wang, L., Yang, D., Zhang, C., et al. (2021). "Effect of Fecal Microbiota Transplantation on Neurological Restoration in a Spinal Cord Injury Mouse Model: Involvement of Brain-Gut Axis." Microbiome 9 (1), 59. doi: 10.1186/s40168-021-01007-y
Kazemian, N., Mahmoudi, M., Halperin, F., Wu, J. C., Pakpour, S. (2020). "Gut Microbiota and Cardiovascular Disease: Opportunities and Challenges." Microbiome 8 (1), 36. doi: 10.1186/s40168-020-00821-0
Khan, R. N., Maner-Smith, K., Owens J, A., Barbian, M. E., Jones R, M., Naudin C, R. (2021). "At the Heart of Microbial Conversations: Endocannabinoids and the Microbiome in Cardiometabolic Risk." Gut Microbes 13 (1), 1–21. doi: 10.1080/19490976.2021.1911572
Kumari, A., Pal Pathak, D., Asthana, S. (2020). "Bile Acids Mediated Potential Functional Interaction Between FXR and FATP5 in the Regulation of Lipid Metabolism." Int. J. Biol. Sci. 16 (13), 2308–2322. doi: 10.7150/ijbs.44774
Li, G., Lin, J., Zhang, C., Gao, H., Lu, H., Gao, X., et al. (2021). "Microbiota Metabolite Butyrate Constrains Neutrophil Functions and Ameliorates Mucosal Inflammation in Inflammatory Bowel Disease." Gut Microbes 13 (1), 1968257. doi: 10.1080/19490976.2021.1968257
Li, Y., Luo, Z. Y., Hu, Y. Y., Bi, Y. W., Yang, J. M., Zou, W. J., et al. (2020). "The Gut Microbiota Regulates Autism-Like Behavior by Mediating Vitamin B(6) Homeostasis in EphB6-Deficient Mice." Microbiome 8 (1), 120. doi: 10.1186/s40168-020-00884-z
Lin, C. Y., Huang, C. H., Wang, W. H., Tenhunen, J., Hung, L. C., Lin, C. C., et al. (2021). "Mono-(2-Ethylhexyl) Phthalate Promotes Dengue Virus Infection by Decreasing IL-23-Mediated Antiviral Responses." Front. Immunol. 12. doi: 10.3389/fimmu.2021.599345
Liu, H. Y., Giraud, A., Seignez, C., Ahl, D., Guo, F., Sedin, J., et al. (2021). "Distinct B Cell Subsets in Peyer's Patches Convey Probiotic Effects by Limosilactobacillus Reuteri." Microbiome 9 (1), 198. doi: 10.1186/s40168-021-01128-4
Liu, Z., Mao, X., Dan, Z., Pei, Y., Xu, R., Guo, M., et al. (2021). "Gene Variations in Autism Spectrum Disorder are Associated With Alteration of Gut Microbiota, Metabolites and Cytokines." Gut Microbes 13 (1), 1–16. doi: 10.1080/19490976.2020.1854967
Manrique, P., Zhu, Y., van der Oost, J., Herrema, H., Nieuwdorp, M., de Vos, W. M., et al. (2021). "Gut Bacteriophage Dynamics During Fecal Microbial Transplantation in Subjects With Metabolic Syndrome." Gut Microbes 13 (1), 1–15. doi: 10.1080/19490976.2021.1897217
Maslanka, J. R., Gu, C. H., Zarin, I., Denny, J. E., Broadaway, S., Fett, B., et al. (2020). "Detection and Elimination of a Novel non-Toxigenic Clostridioides Difficile Strain From the Microbiota of a Mouse Colony." Gut Microbes 12 (1), 1–15. doi: 10.1080/19490976.2020.1851999
Mayneris-Perxachs, J., Arnoriaga-Rodríguez, M., Luque-Córdoba, D., Priego-Capote, F., Pérez-Brocal, V., Moya, A., et al. (2020). "Gut Microbiota Steroid Sexual Dimorphism and Its Impact on Gonadal Steroids: Influences of Obesity and Menopausal Status." Microbiome 8 (1), 136. doi: 10.1186/s40168-020-00913-x
Ma, Y., Zabell, T., Creasy, A., Yang, X., Chatterjee, V., Villalba, N., et al. (2020). "Gut Ischemia Reperfusion Injury Induces Lung Inflammation via Mesenteric Lymph-Mediated Neutrophil Activation." Front. Immunol. 11. doi: 10.3389/fimmu.2020.586685
Murphy, C. L., Barrett, M., Pellanda, P., Killeen, S., McCourt, M., Andrews, E., Shanahan, F., O'Toole, Pw., et al. (2021). "Mapping the Colorectal Tumor Microbiota." Gut Microbes 13 (1), 1–10. doi: 10.1080/19490976.2021.1920657
Naimi, S., Viennois, E., Gewirtz, A. T., Chassaing, B. (2021). "Direct Impact of Commonly Used Dietary Emulsifiers on Human Gut Microbiota." Microbiome 9 (1), 66. doi: 10.1186/s40168-020-00996-6
Nogal, A., Valdes, A. M., Menni, C. (2021). "The Role of Short-Chain Fatty Acids in the Interplay Between Gut Microbiota and Diet in Cardio-Metabolic Health." Gut Microbes 13 (1), 1–24. doi: 10.1080/19490976.2021.1897212
Parker, A., Fonseca, S., Carding, S. R. (2020). "Gut Microbes and Metabolites as Modulators of Blood-Brain Barrier Integrity and Brain Health." Gut Microbes 11 (2), 135–157. doi: 10.1080/19490976.2019.1638722
Prochazkova, P., Roubalova, R., Dvorak, J., Kreisinger, J., Hill, M., Tlaskalova-Hogenova, H., et al. (2021). "The Intestinal Microbiota and Metabolites in Patients With Anorexia Nervosa." Gut Microbes 13 (1), 1–25. doi: 10.1080/19490976.2021.1902771
Qi, X., Yun, C., Pang, Y., Qiao, J. (2021). "The Impact of the Gut Microbiota on the Reproductive and Metabolic Endocrine System." Gut Microbes 13 (1), 1–21. doi: 10.1080/19490976.2021.1894070
Rao, Y., Kuang, Z., Li, C., Guo, S., Xu, Y., Zhao, D., et al. (2021). "Gut Akkermansia Muciniphila Ameliorates Metabolic Dysfunction-Associated Fatty Liver Disease by Regulating the Metabolism of L-Aspartate via Gut-Liver Axis." Gut Microbes 13 (1), 1–19. doi: 10.1080/19490976.2021.1927633
Rutsch, A., Kantsjö, J. B., Ronchi, F. (2020). "The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology." Front. Immunol. 11. doi: 10.3389/fimmu.2020.604179
Saldana-Morales, F. B., Kim, D. V., Tsai, M. T., Diehl, G. E. (2021). "Healthy Intestinal Function Relies on Coordinated Enteric Nervous System, Immune System, and Epithelium Responses." Gut Microbes 13 (1), 1–14. doi: 10.1080/19490976.2021.1916376
Silwal, P., Kim, I. S., Jo, E. K. (2021). "Autophagy and Host Defense in Nontuberculous Mycobacterial Infection." Front. Immunol. 12. doi: 10.3389/fimmu.2021.728742
Sun, N., Meng, F., Zhao, J., Li, X., Li, R., Han, J., et al. (2021). "Aurka Deficiency in the Intestinal Epithelium Promotes Age-Induced Obesity via Propionate-Mediated AKT Activation." Int. J. Biol. Sci. 17 (5), 1302–1314. doi: 10.7150/ijbs.56477
Tiffany, C. R., Lee, J. Y., Rogers, A. W. L., Olsan, E. E., Morales, P., Faber, F., et al. (2021). "The Metabolic Footprint of Clostridia and Erysipelotrichia Reveals Their Role in Depleting Sugar Alcohols in the Cecum." Microbiome 9 (1), 174. doi: 10.1186/s40168-021-01123-9
Tourlousse, D. M., Narita, K., Miura, T., Sakamoto, M., Ohashi, A., Shiina, K., et al. (2021). "Validation and Standardization of DNA Extraction and Library Construction Methods for Metagenomics-Based Human Fecal Microbiome Measurements." Microbiome 9 (1), 95. doi: 10.1186/s40168-021-01048-3
Trikha, S. R. J., Lee, D. M., Ecton, K. E., Wrigley, S. D., Vazquez, A. R., Litwin, N. S., et al. (2021). "Transplantation of an Obesity-Associated Human Gut Microbiota to Mice Induces Vascular Dysfunction and Glucose Intolerance." Gut Microbes 13 (1), 1940791. doi: 10.1080/19490976.2021.1940791
Vicentini, F. A., Keenan, C. M., Wallace, L. E., Woods, C., Cavin, J. B., Flockton, A. R., et al. (2021). "Intestinal Microbiota Shapes Gut Physiology and Regulates Enteric Neurons and Glia." Microbiome 9 (1), 210. doi: 10.1186/s40168-021-01165-z
Wang, B., Huang, Q., Zhang, W., Li, N., Li, J. (2011). "Lactobacillus Plantarum Prevents Bacterial Translocation in Rats Following Ischemia and Reperfusion Injury." Dig. Dis. Sci. 56 (11), 3187–3194. doi: 10.1007/s10620-011-1747-2
Wang, F., Li, Q., He, Q., Geng, Y., Tang, C., Wang, C., et al. (2013a). "Temporal Variations of the Ileal Microbiota in Intestinal Ischemia and Reperfusion." Shock 39 (1), 96–103. doi: 10.1097/SHK.0b013e318279265f
Wang, X., Liu, H., Li, Y., Huang, S., Zhang, L., Cao, C., et al. (2020). "Altered Gut Bacterial and Metabolic Signatures and Their Interaction in Gestational Diabetes Mellitus." Gut Microbes 12 (1), 1–13. doi: 10.1080/19490976.2020.1840765
Wang, F., Li, Q., Wang, C., Tang, C., Li, J. (2012). "Dynamic Alteration of the Colonic Microbiota in Intestinal Ischemia-Reperfusion Injury." PLoS One 7 (7), e42027. doi: 10.1371/journal.pone.0042027
Wang, H., Zhang, W., Zuo, L., Zhu, W., Wang, B., Li, Q., et al. (2013b). "Bifidobacteria may be Beneficial to Intestinal Microbiota and Reduction of Bacterial Translocation in Mice Following Ischaemia and Reperfusion Injury." Br. J. Nutr. 109 (11), 1990–1998. doi: 10.1017/s0007114512004308
Winston, J. A., Theriot, C. M. (2020). "Diversification of Host Bile Acids by Members of the Gut Microbiota." Gut Microbes 11 (2), 158–171. doi: 10.1080/19490976.2019.1674124
Wu, M., Rowe, J. M., Fleming, S. D. (2021a). "Complement Initiation Varies by Sex in Intestinal Ischemia Reperfusion Injury." Front. Immunol. 12. doi: 10.3389/fimmu.2021.649882
Wu, Z., Huang, S., Li, T., Li, N., Han, D., Zhang, B., et al. (2021b). "Gut Microbiota From Green Tea Polyphenol-Dosed Mice Improves Intestinal Epithelial Homeostasis and Ameliorates Experimental Colitis." Microbiome 9 (1), 184. doi: 10.1186/s40168-021-01115-9
Yang, X., Lu, D., Zhuo, J., Lin, Z., Yang, M., Xu, X. (2020). "The Gut-Liver Axis in Immune Remodeling: New Insight Into Liver Diseases." Int. J. Biol. Sci. 16 (13), 2357–2366. doi: 10.7150/ijbs.46405
Yoshiya, K., Lapchak, P. H., Thai, T. H., Kannan, L., Rani, P., Dalle Lucca, J. J., et al. (2011). "Depletion of Gut Commensal Bacteria Attenuates Intestinal Ischemia/Reperfusion Injury." Am. J. Physiol. Gastrointest Liver Physiol. 301 (6), G1020–G1030. doi: 10.1152/ajpgi.00239.2011
Zafar, H., Saier, M. H., Jr. (2021). "Gut Bacteroides Species in Health and Disease." Gut Microbes 13 (1), 1–20. doi: 10.1080/19490976.2020.1848158
Zhang, Y., Ogbu, D., Garrett, S., Xia, Y., Sun, J. (2021). "Aberrant Enteric Neuromuscular System and Dysbiosis in Amyotrophic Lateral Sclerosis." Gut Microbes 13 (1), 1996848. doi: 10.1080/19490976.2021.1996848
Zhao, Q., Huang, J. F., Cheng, Y., Dai, M. Y., Zhu, W. F., Yang, X. W., et al. (2021). "Polyamine Metabolism Links Gut Microbiota and Testicular Dysfunction." Microbiome 9 (1), 224. doi: 10.1186/s40168-021-01157-z
Keywords: intestinal microbiota, metabolites, intestinal ischemia reperfusion, intestinal dysbiosis, biomarkers
Citation: Chen J, Wang Y, Shi Y, Liu Y, Wu C and Luo Y (2022) Association of Gut Microbiota With Intestinal Ischemia/Reperfusion Injury. Front. Cell. Infect. Microbiol. 12:962782. doi: 10.3389/fcimb.2022.962782
Received: 06 June 2022; Accepted: 14 June 2022;
Published: 12 July 2022.
Edited by:
Fan Deng, Southern Medical University, ChinaReviewed by:
Xue-Tao Yan, Shenzhen Bao’an Maternal And Child Health Hospital, ChinaJingjuan Hu, Southern Medical University, China
Copyright © 2022 Chen, Wang, Shi, Liu, Wu and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jingyi Chen, year0216@163.com; Yanrong Luo, 1437785677@qq.com; Chengyi Wu, 250991569@qq.com
†These authors have contributed equally to this work